Associations of CYP2B6, CYP2C19, and CYP2D6 isoforms and phenoconversion with sertraline pharmacokinetics
Begoña Tapia-Alzuguren, Covadonga Canga-Espina, Patricio Molero, Azucena Aldaz · 2026
Read Associations of CYP2B6, CYP2C19, and CYP2D6 isoforms and phenoconversion with sertraline pharmacokinetics by Begoña Tapia-Alzuguren, Covadonga Canga-Espina, Patricio Molero, Azucena Aldaz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351241.txt.
Description
Begona Tapia-Alzuguren and colleagues looked at why blood levels of sertraline, a common mood drug, vary so much between patients. Genes that break the drug down differ by person, and other drugs can speed or slow those pathways. Records covered seven hospital patients with gene data and sixteen drug level checks in routine care.
Before drug clashes were counted, level patterns matched gene based groups for one pathway best, called CYP2B6 in lab shorthand. After counting other drugs, patterns for that pathway grew clearer, and a second pathway also showed useful links. A third pathway showed no steady link. Even in seven patients, the message is plain: genes alone do not set dose, the full drug list matters.
Catalog record
| CREATOR | Begoña Tapia-Alzuguren, Covadonga Canga-Espina, Patricio Molero, Azucena Aldaz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51024 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |